Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Melanoma Research|November 15, 2011
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trialMaja A Hofmann, Axel Hauschild, Peter Mohr, et al.
Journal of Neuroimmunology|January 22, 2013
GABAB receptor antibodies in paraneoplastic cerebellar ataxiaSven Jarius, Florian Steinmeyer, Astrid Knobel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanomaMichele Maio, Andrzej Mackiewicz, Alessandro Testori, et al.
The Journal of Investigative Dermatology|February 25, 2006
Absence of classical MAP kinase pathway signalling in Merkel cell carcinomaRoland Houben, Barbara Michel, Claudia S Vetter-Kauczok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupAgop Y Bedikian, Michael Millward, Hubert Pehamberger, et al.
Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [And] International Society for Digital Imaging of Skin (ISDIS) [And] International Society for Skin Imaging (ISSI)|January 29, 2013
Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanomaPeter Mohr, Ulrik Birgersson, Carola Berking, et al.
Cancer Immunology, Immunotherapy : CII|September 5, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsBenjamin Weide, Thomas Eigentler, Chiara Catania, et al.
Cancer Research|August 4, 2004
Immunogenicity of constitutively active V599EBRafMads Hald Andersen, Joachim Fensterle, Selma Ugurel, et al.
The Journal of Investigative Dermatology|May 13, 2011
Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinomaDavid Schrama, Wiebke K Peitsch, Marc Zapatka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaAxel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
Pageof 7